GABLOFEN (baclofen injection) by Piramal Pharma is gaba a agonists [moa]. First approved in 2010.
Drug data last refreshed 10h ago · AI intelligence enriched 4d ago
GABLOFEN is a baclofen injection administered intrathecally for the treatment of spasticity, working as a GABA-A agonist to reduce muscle tone. It represents a specialized injectable formulation of baclofen for patients requiring direct spinal delivery. The drug targets severe spasticity unresponsive to oral therapies.
LOE-approaching status signals declining commercial resources and team contraction; focus shifts to managed decline and existing patient retention.
GABA A Agonists
gamma-Aminobutyric Acid-ergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump
GABLOFEN offers limited career momentum given its LOE-approaching status and minimal linked job postings; however, roles focus on managed decline, payer negotiations, and patient support. Professionals should expect contracting team size and transition opportunities to other pipeline assets.
Worked on GABLOFEN at Piramal Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo